Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 182

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Naratriptan as Short‐Term Prophylaxis of Menstrually Associated Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Study

Open access
Newman, L., Mannix, L.K., Landy, S., Silberstein, S., Lipton, R.B., Putnam, D.G. Pait, Watson, C., Jöbsis, M., Batenhorst, A., O'Quinn, S. · 2001 · Headache: The Journal of Head and Face Pain

Abstract

Objective.—To determine the efficacy of naratriptan 1‐mg and 2.5‐mg tablets twice daily compared with placebo as short‐term prophylaxis of menstrually associated migraine. Background.—Approximately 60% of women with migraine report headaches associated with their menstrual cycles. Results from an open‐label study suggest that short‐term administration of sumatriptan is useful in the prophylaxis of menstrually associated migraine. Methods.—A randomized, double‐blind, three‐arm, parallel‐group, placebo‐controlled study was conducted in women aged 18 years or older with a history of migraine with or without aura, as defined by the International Headache Society, of at least 6 months. Two dose strengths of naratriptan (1 mg, 2.5 mg) or identical‐appearing placebo tablets (1:1:1) were administered twice daily for 5 days starting 2 days prior to the expected onset of menses across four perimenstrual periods. End points included the number of menstrually associated migraines, total migraine days, peak headache severity, lost work/activity time, migraine‐related quality of life, and incidence of adverse events. Results.—Overall, the intent‐to‐treat population comprised 206 women (naratriptan 1 mg, n = 70; naratriptan 2.5 mg, n = 70, and placebo, n = 66); 171 women treated four perimenstrual periods. Significantly more perimenstrual periods per subject treated with naratriptan, 1 mg, were headache‐free compared with placebo (50% versus 25%, P = .003). Naratriptan, 1 mg, significantly reduced the number of menstrually associated migraines (2.0 versus 4.0, P < .05) and menstrually associated migraine days (4.2 versus 7.0, P < .01) compared with placebo. More patients treated with naratriptan, 1 mg, were headache‐free across all treated perimenstrual periods compared with placebo (23% versus 8%). No difference in headache severity was observed in breakthrough headaches. The incidence and severity of adverse events was similar across treatment groups. Naratriptan, 2.5 mg, was not statistically superior to placebo for any measure. Conclusions.—Naratriptan, 1 mg, with tolerability similar to placebo, is an effective, short‐term, prophylactic treatment for menstrually associated migraine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1526-4610.2001.111006248.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 182

Metadata

Authors
Newman, L., Mannix, L. K., Landy, S., Silberstein, S., Lipton, R. B., Putnam, D. G. P., Watson, C., Jöbsis, M., Batenhorst, A., & O'Quinn, S.
Venue
Headache: The Journal of Head and Face Pain
Publisher
Wiley
Published
2001-03-30
Volume
41
Issue
3
Pages
248-256
ISSN
  • 0017-8748 (ISSN-L)
  • 1526-4610
OpenAlex
W2019449463
Cited by
182
References
2
FWCI
6.28
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Naratriptan as Short‐Term Prophylaxis of Menstrually Associated Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Study. https://app.cochat.ai/papers/10.1046/j.1526-4610.2001.111006248.x
The paper
Newman, L., Mannix, L. K., Landy, S., Silberstein, S., Lipton, R. B., Putnam, D. G. P., Watson, C., Jöbsis, M., Batenhorst, A., & O'Quinn, S. (2001). Naratriptan as Short‐Term Prophylaxis of Menstrually Associated Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Study. Headache: The Journal of Head and Face Pain. https://doi.org/10.1046/j.1526-4610.2001.111006248.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.